Boston, MA -- (SBWIRE) -- 09/12/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (Neuralstem, Inc. (NYSEMKT:CUR), Rockwell Medical Inc(NASDAQ:RMTI), Golden Star Resources Ltd. (USA) (NYSEAMEX:GSS), Dynavax Technologies Corporation (NASDAQ:DVAX)
Neuralstem, Inc. (NYSEMKT:CUR) shares climbed 2.34% and closed at $2.19. The company on Sept. 10 announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at Emory University Hospital in Atlanta, Georgia. The Phase II dose escalation and safety trial, taking place at Emory and at the University of Michigan Health System, is designed to treat up to 15 patients in five different dosing cohorts. All of the patients will be ambulatory and reside within the geographic region of the research center where they will participate.
Is CUR A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Rockwell Medical Inc(NASDAQ:RMTI) shares declined 1.06% to $8.42. The company on Sept. 4 said its lead experimental drug met the main goal of improving hemoglobin levels in its final late-stage trial among adult patients with chronic kidney disease. The study was the second of two identical late-stage studies testing the drug in patients with chronic kidney disease on hemodialysis — a process by which waste and extra fluid is removed from the blood of patients with kidney failure.
Is RMTI A Good Buy After The Recent Price Movement? Find Out Here
Golden Star Resources Ltd. (USA) (NYSEAMEX:GSS) shares increased 3.65% to $0.519. The company on August 12 reported its financial results for the second quarter ended June 30, 2013. Net loss attributable to Golden Star shareholders in the second quarter of 2013 was $128.8 million, compared with a net income of $0.04 million for the same period of 2012. The adjusted net loss attributable to Golden Star shareholders2 for the second quarter of 2013 was $19.8 million compared with adjusted net income of $8.2 million for the same period of 2012.
How Should Investors Trade GSS After The Recent Volatility? Get Free Report Here
Dynavax Technologies Corporation (NASDAQ:DVAX) shares increased 0.84% to $1.20. Zeldes Haeggquist & Eck, LLP, a shareholder and consumer rights litigation firm, on August 16 has commenced an investigation into Dynavax Technologies Corporation to determine whether certain officers and directors of the Company breached their fiduciary duties to shareholders. Dynavax is a clinical-stage biopharmaceutical company focused on the discovery and development of products for the prevention and treatment of infectious and inflammatory diseases. The investigation concerns the clinical trial of Dynavax's lead product candidate, HEPLISAV(TM) ("HEPLISAV"), a Phase III investigational hepatitis B vaccine.
How Should Investors Trade DVAX After The Recent Volatility? Get Free Report Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)